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Summary
Aims of the study. — To assess mortality in people ≥75 years of age 6 months after myocardial
infarction complicated by cardiogenic shock and treated by angioplasty with complete
revascularisation and optimal anti-thrombotic treatment; to compare results to those of
younger patients with or without shock and to analyse predictive factors for death.
Materials and methods. — The study is based on 1011 consecutive patients with myocardial
infarction admitted for primary angioplasty, subdivided into four groups by age and the
presence or absence of cardiogenic shock: group 1 (<75 years of age without shock, n=733),
group 2 (<75 years of age with shock, n=49), group 3 (≥75 years of age without shock, n=208)
and group 4 (≥75 years of age with shock, n=20). These four patient groups were compared for
mortality rates and predictive factors for in-hospital and 6 month mortality. 
Results. — In-hospital mortality in groups 1 to 4 was 1.7%, 30.6%, 9.1%, and 70% (p<0.0001)
respectively and 6-month mortality was 3.1%, 40%, 16% and 78% (P<0.0001). By univariate
analysis renal failure was a predictive factor for death at 6 months in patients without
cardiogenic shock (groups 1 and 3), and left ventricular function in patients in group 2. No
predictive factors were found in group 4 patients. The independent predictive factors for death
at 6 months were: age >75 years of age (P<0.0003), cardiogenic shock (P<0.0001), triple vessel
lesions (P<0.01) and creatinine clearance (P=0.004).
Conclusion. — Mortality after angioplasty remains high in people ≥75 years with cardiogenic
shock despite all the advances in the management of myocardial infarction. These
disappointing results should encourage us to assess the role of surgical revascularisation and
circulatory assistance.
© 2008 Published by Elsevier Masson SAS.
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Résumé
Buts de l’étude – Évaluer la mortalité des sujets d’âge ≥ 75 ans 6 mois après infarctus du
myocarde compliqué de choc cardiogénique et traités par angioplastie avec revascularisation
complète et traitement antithrombotique optimal ; comparer les résultats à ceux des patients
plus jeunes avec ou sans choc, et analyser les facteurs prédictifs de décès.
Matériels et méthodes – L’étude porte sur 1 011 patients consécutifs avec infarctus du myocarde
admis pour angioplastie primaire, subdivisés en quatre groupes selon l’âge et la présence d’un
choc cardiogénique : groupe 1 (< 75 ans sans choc, n = 733), groupe 2 (< 75 ans avec choc, n = 49),
groupe 3 (≥ 75 ans sans choc, n = 208) et groupe 4 (≥ 75 ans avec choc, n = 20). Ces quatre groupes
de patients ont été comparés en termes de taux et de facteurs prédictifs de mortalité intra
hospitalière et à 6 mois.
Résultats – La mortalité intra hospitalière dans les groupes 1 à 4 est respectivement de 1,7 %,
30,6 %, 9,1 %, 70 % (p < 0.0001) et à six mois de 3,1 %, 40 %, 16 %, 78 % (P < 0.0001). En analyse
univariée, l’insuffisance rénale est un facteur prédictif de décès à 6 mois chez les patients sans
choc cardiogénique (groupes 1 et 3), et la dysfonction ventriculaire gauche chez les patients du
groupe 2. Aucun facteur prédictif n’est retrouvé chez les patients du groupe 4. Les facteurs
indépendants prédictifs de décès à 6 mois sont : l’âge > 75 ans (P < 0,0003), le choc cardiogénique
(P < 0,0001), les lésions tri tronculaires (P < 0,01) et la clairance de la créatinine (P = 0,004).
Conclusion. – La mortalité après angioplastie reste très élevée chez les sujets ≥ 75 ans avec
choc cardiogénique malgré tous les progrès dans la prise en charge de l’infarctus du myocarde.
Ces résultats décevants doivent inciter à évaluer la place de la revascularisation chirurgicale
et de l’assistance circulatoire.
© 2008 Published by Elsevier Masson SAS.
Introduction
Between 5 to 10% of myocardial infarctions are complicated
by cardiogenic shock, which remains the most worrying
complication of myocardial infarction and is the main cause
of in-hospital deaths. Most cases of cardiogenic shock deve-
lop in the first days following admission. In the SHOCK study
(SHould we emergently revascularise Occluded coronaries
for Cardiogenic shocK) [1], 75% of the patients developed
shock during the first 24 hours following their admission. 
Fibrinolysis in the acute phase of the infarction reduces the
risk of developing cardiogenic shock in patients without initial
haemodynamic complications but does not improve patient
prognosis if the infarction has already been complicated by
cardiogenic shock [2]. The improvement in prognosis in
patients with infarction and initial cardiogenic shock relies on
early revascularisation, intra-aortic balloon pumping and
optimal medical management. The mortality rate from post-
infarction cardiogenic shock has fallen since the advent of
revascularisation techniques, from 70 to 80% in 1975 to less
than 50% now. This benefit however is seen mostly in younger
patients, with the mortality rate in patients under 75 years of
age falling from 55.8% in 1995 to 39.5% in 2004 in the meta
analysis by Babaev [3], whereas the benefit in patients over
75 years of age is more limited (69.9% in 1995 vs 64% in 2004).
In the SHOCK study, which randomised revascularisation
against medical treatment in patients with acute infarction
complicated by cardiogenic shock, revascularisation reduced
the risk of death at 6 months by 30% in patients under 75 years
of age although increased mortality by 41% compared to
medical treatment alone in patients over 75 years of age [1].
The limitations of the SHOCK study are that it included a small
number of patients (only 16 patients ≥75 years of age revascu-
larised, of which 10 underwent angioplasty), with sub-optimal
anti-thrombotic treatment, and low successful revascularisa-
tion (77%), coronary stenting (33%) and complete revasculari-
sation (23%) rates. Conversely, in the SHOCK register, in-hos-
pital mortality of patients ≥75 years of age was lower after
revascularisation (48% vs 79% in non-revascularised patients)
[4]. The benefits and selection criteria for primary angio-
plasty in patients ≥75 years of age with infarction complicated
by cardiogenic shock are therefore controversial. 
The aims of this study were: .to assess mortality in people ≥75 years of age 6 months
after myocardial infarction complicated by cardiogenic
shock due to predominant left ventricular dysfunction
and treated according to current recommendations by
angioplasty with complete revascularisation and optimal
anti-thrombotic treatment, .to compare these results to those in younger patients
with or without shock.
Patients and methods
The study was conducted at the Pitié-Salpêtrière Hospital
Institute of Cardiology between January 2000 and Decem-
ber 2005. It was based on 1011 consecutive patients admit-
ted for myocardial infarction within 12 hours, investigated
by emergency coronary angiography for revascularisation
by primary angioplasty.
The patients were divided into 4 groups by age and pre-
sence or absence of cardiogenic shock: group 1 (patients
<75 years of age without cardiogenic shock: 733 patients,
73%), group 2 (patients <75 years of age with cardiogenic
shock: 49 patients, 5%), group 3 (patients ≥75 years of age
without cardiogenic shock: 208 patients, 20%), group
4 (patients ≥75 years of age with cardiogenic shock:
20 patients, 2%). These 4 groups of patients were compared in
terms of clinical, laboratory and angiographic features and by
the death rates and predictive factors for death at 6 months.
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All the patients underwent emergency coronary angio-
graphy. The approach for the angioplasty was usually
radial, including those patients with cardiogenic shock in
whom angioplasty was conducted under an intra-aortic bal-
loon pump inserted via the femoral artery. All the angio-
plasties were performed under aspirin, clopidogrel, LMWH
and antiGP IIb/IIIa (abciximab). The great majority of
stents implanted were uncoated. The primary angioplasty
was limited to the artery responsible for the infarction
except for patients with cardiogenic shock in whom com-
plete revascularisation by angioplasty was performed on all
accessible lesions, consistent with ACC/AHA 2004 and ESC
2005 recommendations [5]. All the patients in cardiogenic
shock were treated with intravenous positive inotropes,
mechanical ventilation in cases of refractory hypoxia and
all were put on an intra-aortic balloon pump. Data were
collected from the patients’ medical dossiers and/or by
telephone for the 6-month follow up. 
The diagnosis of myocardial infarction was made on admis-
sion, based on clinical findings (typical pain) with ST segment
elevation, confirmed retrospectively from a rise in the tropo-
nin. The diagnosis of cardiogenic shock was based on systolic
arterial blood pressure < 90 mmHg for at least 30 minutes with
clinical signs of tissue hypoperfusion and clinical signs of left
heart failure and echocardiographical findings of left ventricu-
lar dysfunction, either on admission or during the hospitalisa-
tion. Left ventricular dysfunction was considered to be a pre-
dominant component of the cause of shock when none of the
following causes were present: isolated right ventricular dys-
function, mechanical complication (mitral incompetence or
septal rupture), cardiac tamponade or rupture, severe valve
disease, excessive beta-blocker or calcium blocker treatment
[1]. Renal dysfunction was defined as creatinine clearance
<60 ml/min. A past history of diabetes was defined as two fas-
ting blood glucose concentrations over 1.26 g/l distant to any
acute coronary episode. Hypertension was defined by an arte-
rial blood pressure above 140/90 mmHg or treatment with
antihypertensive agents. 
Statistical analysis 
Results were expressed as mean +/- standard deviation or as
percentages. Qualitative data were compared by the Chi2 test
or Fisher’s exact test and quantitative variables by analysis of
variance. The statistical significance threshold was a value of
p<0.05. Predictive factors for death at 6 months were inves-
tigated using multivariate analysis with logistic regression
from the predictive factors identified in the univariate analy-
sis. Data were analysed on Statview statistics software.
Results
The clinical and angiographical features of the 1011
patients are shown in table 1. Angioplasty was not perfor-
med in 115 patients (11.4%) because of death on table,
lesions inaccessible to angioplasty, emergency surgical
revascularisation indicated or absence of any significant
lesion. Of those patients who underwent angioplasty, 93.9%
were TIMI 3 and 6.1% were TIMI 2 post-angioplasty. The
comparisons of clinical, laboratory, echocardiographical
and angiographical features of the four patient groups are
shown in table 2. 
Follow up data were available on 90% of patients at one
month and on 87% at six months. Cardiogenic shock occurred
in 69 patients (6.8%). The risk of developing cardiogenic
shock was not influenced by age: 6.2% in patients <75 years
of age versus 8.8% in older patients. The overall in-hospital
death rate was 6% (61 deaths) and the 6 month death rate
was 7.7% (78 deaths). In-hospital and 6 month mortality rates
were very significantly different in the four groups. The in-
hospital death rates for groups 1 to 4 were 1.7%, 30.6%, 9.1%
and 70% (p<0.0001) and 6-month death rates were 3.1%, 40%,
16% and 78% (p<0.0001) (table 2) (figure 1).
Table 1 Characteristics of the overall population.
Patient characteristics number (%)
Mean 62±14 year old
Male sex 786 (77.8%)
Diabetes 175 (17.3%)
Renal failure 252 (25.1%)
Hypertension 389 (38.5%)
Smoking 558 (55.3%)
BMI ≥30 139 (13.8%)
LVEF, echocardiographic 50±12%
Cardiogenic shock 69 (6.8%)
Coronary artery lesions 
Triple vessel 183 (18.1%)
Two vessel 297 (29.4%)
Single vessel 522 (51.6%)
Insignificant lesion 9 (0.9%)
Localisation of the infarction
Anterior 432 (42.8%)
Inferior 431 (42.6%)
Lateral 139 (13.8%)
Not established 9 (0.9%)
Figure 1. Deaths depending on age and the presence of cardiogenic
shock (1: <75 years of age without cardiogenic shock, 2: <75 years of
age with cardiogenic shock, 3: ≥75 years of age without cardiogenic
shock, 4: ≥75 years of age with cardiogenic shock).
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The predictive factors for death at 6 months in the
4 groups are illustrated comparatively in table 3. In group 1
(<75 years of age without cardiogenic shock): age, triple ves-
sel lesions and low creatinine clearance were three predic-
tive factors for death. In group 2 (<75 years of age with car-
diogenic shock), LVEF was the only predictive factor for death
(27±16 versus 41±8 P=0.0002). In the third group (>75 years of
age without cardiogenic shock), age (p=0.0004) and creati-
nine clearance (p=0.001) were both predictive factors for
death and no predictive factors for death were found in
group 4 (>75 years of age with cardiogenic shock). 
Age and cardiogenic shock were both highly significant
predictive factors for in-hospital death and at 6 months by
univariate analysis in the overall population (p=0.00001).
Similarly, initial left ventricular ejection fraction was signi-
ficantly lower in patients who had died at 6 months (41±19
versus 51±11 p<0.001). Renal failure was a predictive factor
for death both in-hospital (11.5% versus 4.2%, p<0.0001),
and at six months (18.9% versus 5.7%, p<0.0001). Initial
creatinine clearance was 53.3±39.5 ml/min in patients who
died and 83.6±34.8 ml/min in patients who were alive at
6 months (p<0.0001). Female sex was a predictive factor
for death at 6 months (12% in women versus 6% in men,
p=0.03), although the risk of in-hospital death was identical
for both sexes (p=0.16). 
By multivariate analysis in the overall population, the inde-
pendent predictive factors for in-hospital and 6-month death
were over 75 years of age, cardiogenic shock, triple vessel
disease and renal failure (table 4). Conversely, diabetes, site
of the infarction, LVEF, and sex were not independent predic-
tive factors for in-hospital or 6-month death (table 4).
Discussion
The 6-month death rate after primary angioplasty was 78%
in patients over 75 years of age with cardiogenic shock in
our study. Despite optimal management following the most
recent recommendations [5], the mortality rate in patients
with cardiogenic shock is still twice as high in patients over
75 years of age compared to younger patients. In contrast
Table 2 Comparison of clinical, biological, echocardiographical characteristics and patient prognosis depending on
age and the presence of cardiogenic shock.
<75 years of age
without cardiogenic 
shock
<75 years of age
with cardiogenic 
shock
≥75 years of age
without cardiogenic 
shock
≥75 years of age
with cardiogenic 
shock
P
Sex (F) 14.1% 26.5% 47.5% 45% <0.0001
Diabetes 15.4% 27% 24.5% 40% 0.004
Creatinine 
clearance (ml/min)
92.5±32 78.8±40.7 47.9±18 40.4±17 0.0001
LVEF 52±10 36±12 46±12 30±14 <0.0001
Triple vessel 
disease
15% 38% 25% 37% 0.0001
Anterior infarction 39% 67% 49% 59% 0.002
In-hospital death 1.7% 30.6% 9.1% 70% <0.0001
6 month death 3.1% 40% 16% 78% <0.0001
Table 3 Comparison of predictive factors for death at 6 months depending on age and presence of cardiogenic shock. 
Pts <75 years of age
without cardiogenic 
shock
Pts <75 years of age
with cardiogenic shock 
Pts ≥75 years of age
without cardiogenic 
shock 
Pts ≥75 years of age 
with cardiogenic 
shock 
Dead Alive Dead Alive Dead Alive Dead Alive
Age 61 56 * 61 63 85 81 §§ 82 79
Diabetes 10% 16% 26.6% 29% 18% 21% 43% 25%
Creatinine clearance 
(ml/min)
72 93** 76 70 36 50 § 43 45
LVEF 49 52 27 41*** 47 47 28 30
Anterior infarction 42% 39,6 66,6% 72,7% 39% 52,5% 54% 50%
Triple vessel atheroma 26.6% 14%¤ 33.3% 43.4% 45% 22.5% 38.4% 50%
*p=0.01, **p=0.048, §p=0.0004, §§p=0.001, ¤p=0.054
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to patients without cardiogenic shock or to patients
<75 years of age, no predictive factors for survival at
6 months were found in the elderly group of patients with
cardiogenic shock. 
In the randomised SHOCK study of 302 patients with myo-
cardial infarction complicated by cardiogenic shock, revas-
cularisation in >75 year old patients was associated with
increased mortality compared to medical treatment [1].
The very high mortality rate seen in our study in >75 years
old patients with cardiogenic shock is similar to the 80%
1 year mortality rate in >75 years old patients treated with
angioplasty in the randomised SHOCK study. In contrast to
our study, the patients randomised to revascularisation in
the SHOCK study could undergo either angioplasty or coro-
nary artery bypass grafting. Patients revascularised surgi-
cally had higher co-morbidities than those revascularised by
angioplasty (diabetes was more common, more widespread
lesions). The revascularisation method impacted on the sur-
vival when age was taken into account. One year survival in
patients <75 years of age was 56% after angioplasty and 46%
after bypass whereas one year survival in >75 years old
patients was only 20% after angioplasty (vs 50% after
bypass). The superiority of bypass over angioplasty in
>75 years old patients with cardiogenic shock was attribu-
ted to more complete revascularisation from surgery [6].
The 6 month survival in this patient group in our study was
only 22% despite complete revascularisation by angioplasty
in multi-vessel disease, consistent with ESC recommenda-
tions 2005 [5]. 
In the German, ALKK, register, of 1333 patients in cardio-
genic shock treated by primary angioplasty, age was a pre-
dictive factor for death, with an in-hospital mortality rate
of 30% under 55 years of age, 36% for 55 to 65 years of age,
54% from 65 to 75 years of age and 63% over 75 years of age
[7]. The authors concluded that an invasive emergency
strategy was useful in young patients in cardiogenic shock
whereas the benefit of revascularisation over 75 years of
age remained to be proven.
Dzavik examined the influence of age on prognosis in
patients with cardiogenic shock in the SHOCK register [4].
Of the 277 >75 year old patients, 20 died within the first
3 hours. Of the 257 patients who had not died by hour 3, the
in-hospital mortality was 48% in the 56 revascularised
patients (6% by bypass, 16% by angioplasty), vs 79% in non-
revascularised patients. The benefit of revascularisation
over conservative treatment was similar in <75 year old
patients (42% in-hospital mortality after bypass for angio-
plasty vs 57% with conservative treatment). More > 75 year
old patients treated with revascularisation had a past his-
tory of hypertension, inferior infarction or past history of
angioplasty than medically treated patients. After adjus-
ting for these variables and excluding deaths within the
first 3 hours, revascularisation after 75 year of age was still
associated with a reduction in risk of mortality (RR 0.46,
p<0.002) [4]. Unlike the randomised SHOCK study, this
register therefore supported revascularisation in >75 year
old patients with cardiogenic shock. This discrepancy may
be explained by appropriate patient selection using clinical
and angiographical criteria, as revascularisation was only
performed in 22% of >75 year old patients in the SHOCK
register. 
The in-hospital mortality rate in >75 year old patients in
cardiogenic shock in our series was 70% despite the syste-
matic use of intra-aortic balloon pump, assisted ventilation
in cases of refractory hypoxia [8], triple anti-aggregant
treatment and LMWH, IV positive inotropes and complete
angioplasty revascularisation of all accessible lesions in
accordance with current recommendations. This very high
mortality rate does not support generalising revascularisa-
tion to patients >75 years age in cardiogenic shock and the
decision to use an invasive approach in these patients must
be made on an individual case basis. The clinical selection
criteria for elderly patients remain to be identified as most
of the predictive factors for death in the literature are
angiographic and are therefore available after the coronary
angiography has been performed: the predictive factors for
1 year death in the SHOCK study were the lesion responsi-
ble, multi-vessel disease and end of procedure TIMI grade
[9]. Reduced left ventricular ejection fraction was a predic-
tive factor for death in patients <75 years of age with car-
diogenic shock in our study, consistent with what has been
reported in the literature [10-12], but was not found in
patients over 75 years of age. The same applies to renal
failure and, in some studies, female sex and diabetes [13-
16], which were predictive factors for death under 75 years
of age, but not in older patients with cardiogenic shock. 
The benefit of and selection criteria for primary angio-
plasty in patients over 75 years of age with myocardial
infarction complicated by cardiogenic shock are therefore
debatable. According to ACC/AHA 2004 recommendations,
patients with a myocardial infarction complicated by car-
diogenic shock should undergo early revascularisation if
they are under 75 years of age (recommendation IA) but
this is only considered to be reasonable in some >75 year
old patients selected according to their prior functional sta-
tus (recommendation IIa B).
The improvement in prognosis in patients with cardioge-
nic shock may be due to advances in circulatory assistance.
Whilst the intra-aortic balloon pump is now systematically
implanted, the indications for percutaneous circulatory
assistance with Impella (2.5 l/min flow rate in 12F, 5 l/min
in 21F) or with Tandemheart (3 to 4 l/min) are still being
assessed (common vascular complications, haemorrhage,
haemolysis). This also applies to surgical circulatory assis-
tance (ECMO, artificial heart) which is currently indicated
for patients in whom percutaneous methods are ineffective
and patients who cannot be weaned off percutaneous
methods. In the experience of the Rouen University Hospi-
Table 4 Independent predictive factors for death by
multivariate analysis.
Predictive 
factors for death
in-hospital 
death (p)
1 month 
deaths (p)
6 month 
deaths (p)
Age ≥75 years 0.014 0.02 0.0003
Cardiogenic shock <0.0001 <0.0001 0.0001 
Triple vessel 
disease
0.01 0.02 0.01
Creatinine clearance 0.007 0.004 0.004
Diabetes 0.3 0.6
Site of infarction 0.5 0.8 0.7
LVEF 0.2 0.1 0.1
Sex 0.9 0.9 0.9
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tal, ECMO enabled 4 out of 10 patients to survive the acute
phase of a myocardial infarction complicated by cardioge-
nic shock and refractory to conventional treatment [17].
The selection criteria for method of revascularisation
remain to be established in these patients, as survival in
>75 year old patients with cardiogenic shock was better in
several series after bypass than after angioplasty [1, 6].
Limitations of the study
Few patients ≥75 years of age with myocardial infarction
complicated by cardiogenic shock are treated by angio-
plasty. It is not possible from the relatively small number of
patients to identify independent predictive factors for sur-
vival at 6 months. The same limitations apply to the rando-
mised SHOCK study (16 patients ≥75 years of age revascula-
rised, 10 of whom by angioplasty), and the SHOCK register
(56 patients ≥75 years of age revascularised, 41 of whom by
angioplasty). We can only conclude from our study that pro-
gnosis in these patients is not improved despite complete
revascularisation, the systematic use of stents and optimal
anti-thrombotic treatment.
During the inclusion period, surgical revascularisation of
patients with cardiogenic shock was reserved for patients
with mechanical complications (septal rupture, mitral
incompetence) who were excluded from the study. Our
study only therefore considers results of coronary angio-
plasty and cannot be used to assess the results of surgical
revascularisation in cardiogenic shock associated with pre-
dominant left ventricular dysfunction.
Conclusions
Despite advances in coronary angioplasty, complete revas-
cularisation and optimal medical management, the morta-
lity rate in elderly people with myocardial infarction com-
plicated by cardiogenic shock is still very high and the
benefit of systematic angioplasty in these patients has not
been proven. The disappointing results of angioplasty in
these high risk patients should encourage us to assess the
benefit of surgical revascularisation and circulatory assis-
tance.
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